Lexaria Bioscience (LEXX) Change in Account Payables (2010 - 2021)
Lexaria Bioscience (LEXX) posted Change in Account Payables of -$5223.0 for Q4 2021, down 233.96% sequentially from $3899.0 in Q3 2021, and down 118.34% YoY from $28481.0 in Q4 2020.
Lexaria Bioscience (LEXX) Change in Account Payables (2010 - 2021) Analysis & Trends
Lexaria Bioscience has reported Change in Account Payables for 12 years, with the latest figure at -$5223.0 in Q4 2021.
- Quarterly Change in Account Payables fell 118.34% year-over-year to -$5223.0 in Q4 2021, while the trailing twelve-month figure through Aug 2022 was -$5223.0 (up 90.23% YoY) and the FY2022 annual result came in at -$5223.0, up 90.23% from the prior year.
- Change in Account Payables eased to -$5223.0 in Q4 2021 per LEXX's latest filing, from $3899.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $119621.0 in Q1 2021 and troughed at -$243169.0 in Q2 2017.
- A 5-year average of -$16399.6 and a median of $1130.5 in 2018 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2017 and 2019: Change in Account Payables plunged 2857.33% in 2017, then jumped 2259.44% in 2019.
- Over 5 years, Change in Account Payables stood at -$17672.0 in 2017, then surged by 178.08% to $13799.0 in 2018, then slumped by 178.96% to -$10896.0 in 2019, then soared by 361.39% to $28481.0 in 2020, then plunged by 118.34% to -$5223.0 in 2021.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$5223.0, $3899.0, and -$205482.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2021 | -5,223.00 |
| Nov 30, 2021 | -5,223.00 |
| Aug 31, 2021 | 3,899.00 |
| Aug 31, 2021 | 3,899.00 |
| May 31, 2021 | -205,482.00 |
| May 31, 2021 | -205,482.00 |
| Feb 28, 2021 | 119,621.00 |
| Feb 28, 2021 | 119,621.00 |
| Nov 30, 2020 | 28,481.00 |
| Nov 30, 2020 | 28,481.00 |
| Aug 31, 2020 | 29,109.00 |
| Aug 31, 2020 | 29,109.00 |
| May 31, 2020 | 27,995.00 |
| May 31, 2020 | 27,995.00 |
| Feb 29, 2020 | -35,600.00 |
| Feb 29, 2020 | -35,600.00 |
| Nov 30, 2019 | -10,896.00 |
| Nov 30, 2019 | -10,896.00 |
| Aug 31, 2019 | 27,101.00 |
| Aug 31, 2019 | 27,101.00 |